News
-
-
-
-
-
-
-
-
-
-
PRESS RELEASE
Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast
Jaguar Health to host investor webcast on crofelemer's impact on MVID and SBS-IF patient experience, with results of investigator-initiated trial by Dr. Miqdady presented at ELITE PED-GI Congress in Abu Dhabi